November 1 – November 15, 2026 Edition #21

    Trial Watch No. 21

    Fifteen interventional clinical studies with registered start dates inside the first half of November. Three are recorded as actual starts; twelve remain estimates and do not confirm first-patient enrollment.

    15
    High-Signal Trials
    7
    Therapy Areas
    5
    Phase 3 Programs
    Clinical trial intelligence; November 2026 Edition 21
    Twice-Monthly Edition
    November 16, 2026

    This edition at a glance

    Four oncology studies sit alongside investigations of neurology and devices, obesity and diabetes, immune-mediated conditions, infections, Pompe disease, and engineered cell or gene therapies.

    Eleven entries are Phase 2, Phase 2/3, or Phase 3. The remaining four are two Phase 1 studies, a Phase 1/2 study, and a non-phased early-feasibility device investigation. Planned enrollment ranges from four to 390 participants.

    Phase mix

    Other: 1 Phase 2/3, 1 Phase 1/2, 2 Phase 1, 1 not applicable (device).

    Status at compile time

    Trials by therapy area

    Oncology4
    Neurology & devices2
    Cardiometabolic2
    Immunology2
    Infectious disease2
    Rare disease1
    Advanced modalities2

    Oncology

    4 trials
    Oncology · First-line ES-SCLCPhase 2Not yet recruiting
    NCT07895056

    ABBV-706 added to tarlatamab + atezolizumab in first-line extensive-stage small cell lung cancer

    First-line ES-SCLC · Sponsor study ID: M26-386 · Registry snapshot last updated 2026-10-26.

    Lead sponsor
    AbbVieNo collaborators listed
    Planned enrollment
    80participants (estimated)
    Registered start
    November 4, 2026Estimated start, not a confirmed enrollment event
    Primary completion
    August 2031Estimated

    Trial design and endpoints

    Open-label, randomized; two arms, each receiving a different dose of ABBV-706 with tarlatamab and atezolizumab. Registry states about 80 participants at approximately 25 sites worldwide. Primary endpoints: objective response rate by blinded independent central review (RECIST 1.1) and number of participants with adverse events.

    Mechanism and modality

    ABBV-706 is described in published early-phase research as an investigational SEZ6-directed antibody–drug conjugate with a topoisomerase-I inhibitor payload. This study combines IV ABBV-706 with IV tarlatamab and atezolizumab; it does not establish efficacy for the combination.

    Why it matters

    This Phase 2 protocol compares two ABBV-706 dose levels on the same immunotherapy backbone in previously untreated extensive-stage SCLC. Objective response and adverse events are the co-primary measurements; no arm compares this triplet with standard therapy.

    Estimated start · Registry-reported investigational study

    Oncology · Newly diagnosed AMLPhase 3Recruiting
    NCT07925190

    Mesutoclax + azacitidine versus venetoclax + azacitidine in untreated AML

    Newly diagnosed AML · Sponsor study ID: ICP-CL-01210 · Registry snapshot last updated 2026-11-13.

    Lead sponsor
    Beijing InnoCare Pharma Tech Co., Ltd.No collaborators listed
    Planned enrollment
    318participants (estimated)
    Registered start
    November 3, 2026Actual start, reported in registry
    Primary completion
    December 2029Estimated

    Trial design and endpoints

    Randomized, open-label, multicenter. Mesutoclax (ICP-248) + azacitidine versus venetoclax + azacitidine in newly diagnosed AML, age 65 or older, or 18 to under 65 and ineligible for intensive chemotherapy. Primary endpoint: overall survival. Secondary endpoints include CR/CRc rates, MRD-negative CR, event-free survival and transfusion independence.

    Mechanism and modality

    Mesutoclax (ICP-248) is an investigational oral BCL2 inhibitor; azacitidine provides the combination backbone. The active comparator is venetoclax plus azacitidine. BCL2 inhibition is intended to disrupt an anti-apoptotic survival pathway.

    Why it matters

    A head-to-head comparison against a venetoclax-based regimen in older or intensive-chemotherapy-ineligible AML, with overall survival as the single primary endpoint. The registry lists one recruiting site, in Hangzhou, China.

    Actual start · Registry-reported investigational study

    Oncology · Relapsed/refractory myelomaPhase 2Not yet recruiting
    NCT07901868

    GEM-MeziDEL

    Elranatamab + mezigdomide + dexamethasone in relapsed/refractory multiple myeloma

    Relapsed/refractory myeloma · Sponsor study ID matches acronym above · Registry snapshot last updated 2026-10-28.

    Lead sponsor
    PETHEMA FoundationNo collaborators listed
    Planned enrollment
    60participants (estimated)
    Registered start
    November 1, 2026Estimated start, not a confirmed enrollment event
    Primary completion
    December 2031Estimated

    Trial design and endpoints

    Open-label, multicenter. Cycle 1: elranatamab + dexamethasone; cycles 2 to 6: elranatamab + mezigdomide + dexamethasone; cycles 7 to 12: elranatamab + mezigdomide. At end of cycle 12, MRD status decides mezigdomide-alone maintenance (MRD-negative) or continued combination (MRD-positive). Primary endpoint: proportion achieving MRD negativity (fewer than 1 tumor cell in 100,000 by next-generation flow).

    Mechanism and modality

    Elranatamab is a BCMA×CD3-directed T-cell-engaging bispecific antibody; mezigdomide is an investigational cereblon E3 ligase modulator. The protocol sequences them with dexamethasone and adjusts maintenance by measurable residual disease (MRD) status.

    Why it matters

    An MRD-guided sequence in patients with prior lenalidomide exposure who are refractory or intolerant to it. In MRD-negative patients on mezigdomide maintenance, elranatamab can be added on MRD re-positivity or progression. Prior BCMA bispecific therapy is an exclusion; prior BCMA CAR-T or ADC is allowed after more than 6 months. Sites are in Spain.

    Estimated start · Registry-reported investigational study

    Oncology · Endometrial cancerPhase 3Not yet recruiting
    NCT07860450

    SAPPHIRE

    Subcutaneous versus intravenous dostarlimab + carboplatin-paclitaxel in advanced or recurrent endometrial cancer

    Endometrial cancer · Sponsor study ID: 300118 · Registry snapshot last updated 2026-10-19.

    Lead sponsor
    GlaxoSmithKlineNo collaborators listed
    Planned enrollment
    378participants (estimated)
    Registered start
    November 12, 2026Estimated start, not a confirmed enrollment event
    Primary completion
    November 5, 2030Estimated

    Trial design and endpoints

    Open-label, two-part. Part 1 (Phase 1b) selects the subcutaneous dose; Part 2 (Phase 3) randomizes participants to subcutaneous or intravenous dostarlimab, each with carboplatin-paclitaxel. Primary endpoints are pharmacokinetic: Ctrough and AUC of dostarlimab. Secondary endpoints include confirmed ORR, PFS, OS, safety and anti-drug antibodies.

    Mechanism and modality

    Dostarlimab is an anti-PD-1 antibody. This study tests subcutaneous delivery versus intravenous dosing on the same carboplatin–paclitaxel backbone; its primary readouts concern dostarlimab exposure (pharmacokinetics), not a claim of improved survival.

    Why it matters

    The central question is whether subcutaneous dostarlimab can provide relevant pharmacokinetic exposure relative to IV administration when given with carboplatin–paclitaxel. Efficacy and safety remain important secondary measures.

    Estimated start · Registry-reported investigational study

    Neurology & devices

    2 trials
    Neurology & devices · Myasthenia gravisPhase 2Recruiting
    NCT07673744

    Ublituximab maintenance after efgartigimod induction in myasthenia gravis

    Myasthenia gravis · Sponsor study ID: TG1101-MG201 · Registry snapshot last updated 2026-10-29.

    Lead sponsor
    TG Therapeutics, Inc.No collaborators listed
    Planned enrollment
    120participants (estimated)
    Registered start
    November 1, 2026Estimated start, not a confirmed enrollment event
    Primary completion
    July 1, 2028Estimated

    Trial design and endpoints

    Randomized, double-blind, placebo-controlled. Adults with myasthenia gravis who respond to efgartigimod are studied for ublituximab versus placebo as maintenance. Primary endpoint: time to onset of a clinical worsening event, up to Week 24. Secondary endpoints include TEAEs, ublituximab Cmax, CD19+ B-cell counts and change in MG-ADL at Week 24. Seven U.S. sites are listed.

    Mechanism and modality

    Efgartigimod reduces circulating IgG by targeting FcRn; ublituximab is an anti-CD20 B-cell-depleting monoclonal antibody. The trial asks whether maintenance after response to efgartigimod delays clinical worsening.

    Why it matters

    Tests whether a maintenance agent can hold participants who responded to efgartigimod induction, using time to clinical worsening as the primary endpoint over 24 weeks against placebo.

    Estimated start · Registry-reported investigational study

    Neurology & devices · Communication neurotechnologyNot applicableNot yet recruiting
    NCT07933549

    RECLAIM

    Intracortical microelectrodes to support communication in severe neurologic impairment

    Communication neurotechnology · Sponsor study ID: HSC-MS-26-0020 · Registry snapshot last updated 2026-11-12.

    Lead sponsor
    The University of Texas Health Science Center, HoustonNo collaborators listed
    Planned enrollment
    4participants (estimated)
    Registered start
    November 1, 2026Estimated start, not a confirmed enrollment event
    Primary completion
    January 1, 2035Estimated

    Trial design and endpoints

    Early feasibility study of the RECLAIM System in adults aged 22 to 65 with severe communication impairment from ALS, locked-in syndrome, or brain injury including stroke. Primary endpoint: safety (number and type of adverse events from implant to one year). Secondary endpoints include word error rate, phoneme error rate, BLEU and BERT scores every three months for two years.

    Mechanism and modality

    The investigational RECLAIM interface uses intracortical microelectrode recordings from language-related brain networks to decode intended communication. The study is an early feasibility device investigation, not a drug trial.

    Why it matters

    Four participants, one site (Houston), safety as the primary endpoint. Effectiveness is measured by decoding error rates (word and phoneme) and text-similarity scores against reference sentences. Included for the device category; Phase is N/A.

    Estimated start · Registry-reported investigational study

    Cardiometabolic

    2 trials
    Cardiometabolic · Obesity, without diabetesPhase 3Not yet recruiting
    NCT07855900

    SYNCHRONIZE-START

    Survodutide initiation strategies in overweight or obesity without diabetes

    Obesity, without diabetes · Sponsor study ID: 1404-0127 · Registry snapshot last updated 2026-10-27.

    Lead sponsor
    Boehringer IngelheimNo collaborators listed
    Planned enrollment
    350participants (estimated)
    Registered start
    November 7, 2026Estimated start, not a confirmed enrollment event
    Primary completion
    November 6, 2029Estimated

    Trial design and endpoints

    Open-label, pragmatic. Evaluates initiation strategies for survodutide, including de novo use and switching from semaglutide or tirzepatide. Two groups differ by starting dose and prior use of similar weight-loss medicines. Once-weekly subcutaneous injection with gradual dose increase. Primary endpoint: percent change in body weight from baseline to Week 52.

    Mechanism and modality

    Survodutide is an investigational dual glucagon/GLP-1 receptor agonist given subcutaneously. The pragmatic program examines how treatment is initiated, including de novo initiation and switching from semaglutide or tirzepatide.

    Why it matters

    Addresses how a weight-management drug is started in practice, including after other named agents, in adults with BMI of 30 or more (or 27 or more with a weight-related condition) without diabetes. Quality-of-life instruments (IWQOL-Lite-CT, PROMIS) are among the secondary endpoints.

    Estimated start · Registry-reported investigational study

    Cardiometabolic · Type 2 diabetesPhase 2Not yet recruiting
    NCT07796477

    SYH2069 injection in type 2 diabetes: dose-finding against placebo and tirzepatide 15 mg

    Type 2 diabetes · Sponsor study ID: SYH2069-003 · Registry snapshot last updated 2026-09-01.

    Lead sponsor
    CSPC Ouyi Pharmaceutical Co., Ltd.No collaborators listed
    Planned enrollment
    240participants (estimated)
    Registered start
    November 6, 2026Estimated start, not a confirmed enrollment event
    Primary completion
    September 28, 2027Estimated

    Trial design and endpoints

    Randomized, double-blind, placebo- and active-comparator-controlled dose-finding study. Four SYH2069 dose groups (40 participants each), four matched placebo groups (10 each) and tirzepatide 15 mg (40). 28-week treatment period. Population: T2DM inadequately controlled on diet and exercise alone or metformin monotherapy. Primary endpoint: change in HbA1c at Week 28.

    Mechanism and modality

    The registry identifies four dose groups of investigational SYH2069 injection, matching placebo groups and an active tirzepatide 15 mg comparator. A specific receptor target for SYH2069 was not established from the checked study sources.

    Why it matters

    Places four doses of an investigational injectable beside both placebo and tirzepatide 15 mg in one Phase 2 study, with HbA1c at Week 28 as the primary endpoint. Registry lists a site in Nanjing, China.

    Estimated start · Registry-reported investigational study

    Immunology

    2 trials
    Immunology · Cutaneous lupusPhase 2/3Recruiting
    NCT07881120

    DISCOVERY

    Afimetoran in cutaneous lupus erythematosus: a seamless Phase 2/3 design

    Cutaneous lupus · Sponsor study ID: AFI-CLE-201 · Registry snapshot last updated 2026-11-10.

    Lead sponsor
    Beeline Medicines CorporationNo collaborators listed
    Planned enrollment
    390participants (estimated)
    Registered start
    November 3, 2026Actual start, reported in registry
    Primary completion
    April 2030Estimated

    Trial design and endpoints

    Two-stage, operationally seamless, randomized, double-blind, placebo-controlled. Stage 1 compares two afimetoran doses with placebo to select the dose; Stage 2 confirms efficacy and safety. Once-daily oral capsule for 24 weeks, then all participants receive afimetoran for 28 more weeks. Primary endpoints at Week 24: percent change in CLASI-A and CLASI-70 response.

    Mechanism and modality

    Afimetoran is an investigational oral antagonist of toll-like receptors 7 and 8 (TLR7/TLR8). The two-stage protocol selects a dose before confirmatory assessment versus placebo.

    Why it matters

    Combines Phase 2 dose selection and Phase 3 confirmatory evaluation under one protocol in cutaneous lupus that is not adequately controlled by antimalarial therapy. The study began on a registry-reported actual date.

    Actual start · Registry-reported investigational study

    Immunology · Ulcerative colitisPhase 3Recruiting
    NCT07846683

    AMETRINE-SC

    Subcutaneous afimkibart induction for moderately to severely active ulcerative colitis

    Ulcerative colitis · Sponsor study ID: CA46523 · Registry snapshot last updated 2026-10-26.

    Lead sponsor
    Hoffmann-La RocheCollaborators: Chugai Pharmaceutical; Pfizer
    Planned enrollment
    350participants (estimated)
    Registered start
    November 15, 2026Estimated start, not a confirmed enrollment event
    Primary completion
    May 31, 2028Estimated

    Trial design and endpoints

    Multicenter, double-blind, placebo-controlled. Subcutaneous induction therapy with afimkibart in moderately to severely active ulcerative colitis (modified Mayo Score), ages 16 to 80, after inadequate response, loss of response or intolerance to at least one protocol-specified conventional or advanced therapy. Primary endpoint: clinical remission at Week 12.

    Mechanism and modality

    Afimkibart is an investigational monoclonal antibody targeting TL1A, a regulator of inflammatory pathways. The trial tests its subcutaneous induction regimen versus placebo in ulcerative colitis.

    Why it matters

    Advances the anti-TL1A program into subcutaneous induction for ulcerative colitis, with Week 12 clinical remission as the primary endpoint and endoscopic and symptom outcomes as supporting measurements.

    Estimated start · Registry-reported investigational study

    Infectious disease

    2 trials
    Infectious disease · Ebola-BundibugyoPhase 1Not yet recruiting
    NCT07919197

    mRNA-1469 vaccine against Ebola-Bundibugyo virus disease in African participants aged 1 to 65

    Ebola-Bundibugyo · Sponsor study ID: mRNA-1469-P102 · Registry snapshot last updated 2026-11-05.

    Lead sponsor
    ModernaTX, Inc.No collaborators listed
    Planned enrollment
    224participants (estimated)
    Registered start
    November 2, 2026Estimated start, not a confirmed enrollment event
    Primary completion
    February 1, 2028Estimated

    Trial design and endpoints

    Observer-blind, placebo-controlled. Primary endpoints are safety: solicited local and systemic reactions (7 days), unsolicited AEs (28 days), medically attended AEs (about 6 months) and SAEs through Day 337. Secondary endpoints: geometric mean of Bundibugyo ebolavirus-specific binding antibodies and seroresponse at Day 29 through Day 337. Registered site: Uganda Virus Research Institute, Entebbe.

    Mechanism and modality

    The mRNA-1469 vaccine candidate is designed to elicit an immune response against Ebola-Bundibugyo virus. Safety and BDBV-specific antibody responses are assessed; protection against infection is not established by this early-stage study.

    Why it matters

    An mRNA vaccine candidate for Ebola-Bundibugyo virus disease, studied from age 1 through 65 in African participants. Included at Phase 1 as a novel-modality entry for a filovirus. Prior participation in a filovirus vaccine study is an exclusion.

    Estimated start · Registry-reported investigational study

    Infectious disease · Ventilator-associated pneumoniaPhase 3Not yet recruiting
    NCT07804082

    PYOPHANEB

    Nebulized bacteriophages for Pseudomonas ventilator-associated pneumonia

    Ventilator-associated pneumonia · Sponsor study ID: APHP222819 · Registry snapshot last updated 2026-09-04.

    Lead sponsor
    Assistance Publique - Hôpitaux de ParisNo collaborators listed
    Planned enrollment
    184participants (estimated)
    Registered start
    November 3, 2026Estimated start, not a confirmed enrollment event
    Primary completion
    December 3, 2029Estimated

    Trial design and endpoints

    Double-blind, placebo-controlled. Nebulized anti-P. aeruginosa bacteriophages (GMP) delivered by vibrating mesh nebulizer, in addition to conventional IV antibiotics, versus saline placebo. Primary endpoint: proportion alive and cured at Day 28 without recurrence of P. aeruginosa VAP. Secondary endpoints include ventilator-free and antibiotic-free days, mortality, anti-phage antibodies and resistant Gram-negative carriage. Sites are in France.

    Mechanism and modality

    The investigational intervention comprises bacteriophages directed at Pseudomonas aeruginosa, delivered by vibrating-mesh nebulization alongside intravenous antibiotics. The comparator uses nebulized saline alongside usual antibiotic therapy.

    Why it matters

    The registry cites VAP in up to 40% of mechanically ventilated patients with mortality approaching 30%, and two recent randomized trials of adjunctive nebulized antibiotics in Gram-negative VAP that showed no clinical benefit. This study tests nebulized phages as the adjunct instead.

    Estimated start · Registry-reported investigational study

    Rare disease

    1 trial
    Rare disease · Late-onset Pompe diseasePhase 2Not yet recruiting
    NCT07750990

    S-606001 long-term extension in late-onset Pompe disease

    Late-onset Pompe disease · Sponsor study ID: 2507N1223 · Registry snapshot last updated 2026-10-13.

    Lead sponsor
    ShionogiNo collaborators listed
    Planned enrollment
    60participants (estimated)
    Registered start
    November 2, 2026Estimated start, not a confirmed enrollment event
    Primary completion
    August 31, 2028Estimated

    Trial design and endpoints

    Open-label, multicenter extension. Enrolls participants who completed another S-606001 study (for example NCT07123155), including participants whose allocated arm in such a study was terminated by the sponsor. Primary endpoint: treatment-emergent adverse events through Week 96. Secondary endpoints: %FVC, 6-minute walk test, GSGC score and patient-reported outcomes.

    Mechanism and modality

    S-606001 is being developed as an oral substrate-reduction approach to reduce glycogen synthesis in Pompe disease; the registry also lists enzyme replacement therapy (ERT). This extension primarily measures longer-term safety and tolerability.

    Why it matters

    Extends follow-up after earlier S-606001 studies to characterize safety and tolerability over 96 weeks; functional and respiratory outcomes are exploratory or secondary. Its original August start estimate was revised to November.

    Estimated start · Registry-reported investigational study

    Advanced modalities

    2 trials
    Advanced modalities · B-cell malignanciesPhase 1/2Not yet recruiting
    NCT07932496

    CT204V

    In vivo dual-targeting CD19/CD20 CAR-T gene therapy in B-cell malignancies

    B-cell malignancies · Sponsor study ID: R1055C00001 · Registry snapshot last updated 2026-11-12.

    Lead sponsor
    AstraZenecaNo collaborators listed
    Planned enrollment
    160participants (estimated)
    Registered start
    November 9, 2026Estimated start, not a confirmed enrollment event
    Primary completion
    October 15, 2029Estimated

    Trial design and endpoints

    Modular, open-label, single-arm, dose escalation and expansion. Phase 1 primary endpoints: AEs/SAEs, dose-limiting toxicities, AESI. Phase 2 primary endpoints: ORR and CR rate per Lugano, best overall response, duration of response and duration of CR. Secondary endpoints include viral vector and CAR transgene levels in peripheral blood and anti-drug antibodies. Prior VSV-G-containing treatment is an exclusion.

    Mechanism and modality

    An investigational lentiviral vector is intended to generate anti-CD19/CD20 CAR-T cells in vivo, rather than requiring conventional ex vivo CAR-T manufacturing. Long-term safety surveillance is central to this early-phase gene therapy study.

    Why it matters

    The registry describes CAR-T cells generated in vivo by a lentiviral vector, with follow-up for adverse events up to 15 years. Relapsed or refractory B-cell malignancies; participants must have CD19 and/or CD20 expression.

    Estimated start · Registry-reported investigational study

    Advanced modalities · Refractory solid tumorsPhase 1Recruiting
    NCT07672483

    IL-12 genetically engineered myeloid cells (GEMys) in relapsed or refractory solid tumors

    Refractory solid tumors · Sponsor study ID: 10002091 · Registry snapshot last updated 2026-11-12.

    Lead sponsor
    National Cancer Institute (NCI)No collaborators listed
    Planned enrollment
    95participants (estimated)
    Registered start
    November 4, 2026Actual start, reported in registry
    Primary completion
    January 15, 2028Estimated

    Trial design and endpoints

    Dose escalation/de-escalation (Part A) and expansion (Part B) at the NIH Clinical Center, Bethesda. Autologous CD34+ cells collected by leukapheresis are transduced with a lentiviral vector encoding single-chain IL-12 and truncated EGFR, then differentiated into myeloid cells and infused on Day 0. Depending on dose level, cyclophosphamide and fludarabine are given first. Primary endpoints: recommended Phase 2 dose (Part A); post-treatment tumor IL-12 or IFN-gamma increase versus pre-treatment (Part B).

    Mechanism and modality

    The protocol uses autologous hematopoietic stem/progenitor-cell-derived myeloid cells engineered to express interleukin-12 (IL-12). It examines safety and tumor-microenvironment measurements following treatment.

    Why it matters

    Uses an engineered myeloid-cell approach for solid tumors, with tumor biopsies supporting measurement of the local IL-12 signal. The registry now reports a November 4 actual start following several earlier planned-date revisions.

    Actual start · Registry-reported investigational study

    Signal convergence

    What these fifteen records suggest about clinical development approaches; interpretations are limited to this edition's selected studies.

    3studies

    Administration routes as a development variable

    Subcutaneous versus IV dostarlimab is evaluated on drug exposure; subcutaneous afimkibart tests induction in colitis; and nebulized bacteriophages test delivery to the infected lung alongside antibiotics.

    3studies

    Comparative design remains consequential

    Mesutoclax is tested against a venetoclax regimen; SYH2069 includes placebo and tirzepatide groups; and SAPPHIRE compares two routes of the same antibody. Their primary endpoints differ.

    2studies

    Engineered immune interventions in early phases

    CT204V tests in vivo generation of dual CD19/CD20 CAR-T cells, while the NCI IL-12 myeloid-cell study engineers autologous cells to influence the tumor microenvironment. Neither study establishes patient benefit.

    2studies

    Protocol-defined treatment adaptation

    The myeloma protocol uses MRD status to guide maintenance treatment, whereas the cutaneous-lupus study selects an afimetoran dose before confirmatory assessment. These are different forms of response- and dose-informed development.

    2studies

    Feasibility and pharmacokinetics before outcomes

    The four-participant communication-interface study prioritizes safety and feasibility, while SAPPHIRE prioritizes pharmacokinetic exposure. A Phase label or technological novelty should not be confused with demonstrated efficacy.

    Follow every edition of Trial Watch

    Study starts, clinical designs and emerging research signals, twice each month.

    Explore Trial Watch

    Source and editorial methodology

    Reporting window: November 1 to November 15, 2026 inclusive. Fifteen distinct studies list a day-level start date inside this interval; three are marked actual and twelve are estimated in the latest accessible registry-derived records reviewed on November 16, 2026. Estimated start dates are not evidence that enrollment began.

    Each study has two trial-specific links: the corresponding ClinicalTrials.gov record and a checked sponsor study page, National Cancer Institute listing, or registry mirror. Mirrors reproduce ClinicalTrials.gov records and must not be interpreted as independent clinical corroboration. Sponsor protocol identifiers appear in the card data. Scientific context about mechanisms is distinguished from trial outcomes, none of which are implied to establish efficacy.

    Exact NCT identifiers were compared with the supplied Edition 20 archive, with no overlap. A full identifier-level comparison against Editions 1–19 was not completed because their complete historical NCT lists were not supplied. All information may change with later registry amendments. Editorial review does not constitute medical, regulatory, or investment advice.